Sean R. Downing

4.5k citations

26 papers · 882 indexed · h-index 13

Molecular Biology
Pulmonary and Respiratory Medicine top 10%
Oncology top 10%
Cancer Research top 10%
Surgery

Co-authors: Doron Lipson Philip J. Stephens Roman Yelensky Mirna Jarosz Theresa Y. MacDonald Himisha Beltran Juan Miguel Mosquera Garrett M. Frampton
Topics: Cancer Genomics and Diagnostics (6 papers)Prostate Cancer Treatment and Research (5 papers)Cancer Research and Treatments (3 papers)
Cited by: Cancer Research Oncology Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology Bioinformatics Journal of Fluid Mechanics
Partner nations: United States Australia Ecuador

In The Last Decade

Sean R. Downing

26 papers receiving 870 citations

Peers

Countries citing papers authored by Sean R. Downing

Since Specialization

Citations

This map shows the geographic impact of Sean R. Downing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sean R. Downing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sean R. Downing more than expected).

Fields of papers citing papers by Sean R. Downing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sean R. Downing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sean R. Downing. The network helps show where Sean R. Downing may publish in the future.

Co-authorship network of co-authors of Sean R. Downing

This figure shows the co-authorship network connecting the top 25 collaborators of Sean R. Downing. A scholar is included among the top collaborators of Sean R. Downing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sean R. Downing. Sean R. Downing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Colchicine, aspirin, and montelukast – A case of successful combined pharmacotherapy for adult multisystem inflammatory syndrome in COVID-19 2020 ·Journal of Global Infectious Diseases ·Vivek Chauhan,Sean R. Downing,(unknown),Sagar Galwankar,Pushpa Sharma,Stanislaw P. Stawicki	8
2	The InSituPlex® Staining Method for Multiplexed Immunofluorescence Cell Phenotyping and Spatial Profiling of Tumor FFPE Samples 2019 ·Methods in molecular biology ·(unknown),Katir Patel,Mark N. Bobrow,Sean R. Downing	29
3	Abstract 5657: Use of a novel immunofluorescence multiplexing technology, InSituPlex™, for the simultaneous detection of immune cells in multiple cancer types 2018 ·Cancer Research ·Sean R. Downing,Katir Patel,Jamie Buell,Courtney Hebert	3
4	Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2–Targeted Therapy 2014 ·Journal of Clinical Oncology ·Siraj M. Ali,R. Katherine Alpaugh,Sean R. Downing,Philip J. Stephens,Jian Yu,Hong Wu,Jamie Buell,Vincent A. Miller,Doron Lipson,Gary A. Palmer,Jeffrey S. Ross,Massimo Cristofanilli	40
5	Comprehensive Genomic Profiling of Relapsed and Metastatic Adenoid Cystic Carcinomas by Next-generation Sequencing Reveals Potential New Routes to Targeted Therapies 2014 ·The American Journal of Surgical Pathology ·Jeffrey S. Ross,Kai Wang,(unknown),Christine E. Sheehan,Timothy A. Jennings,Rami N. Al‐Rohil,Geoff Otto,(unknown),Gary A. Palmer,Sean R. Downing,Roman Yelensky,Doron Lipson,Sohail Balasubramanian,Lázaro Ibrahim Romero García,(unknown),Siraj M. Ali,Vincent A. Miller,Philip J. Stephens	50
6	Abstract 4699: Analytical validation of solid tumor fusion gene detection in a comprehensive NGS-based clinical cancer genomic test 2014 ·Cancer Research ·Roman Yelensky,Amy Donahue,Geoff Otto,Michelle Nahas,Jie He,Frank Juhn,Sean R. Downing,Garrett M. Frampton,Juliann Chmielecki,Jeffrey S. Ross,Maureen F. Zakowski,Marc Ladanyi,Vincent A. Miller,Philip J. Stephens,Doron Lipson	1
7	Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy 2013 ·Modern Pathology ·Jeffrey S. Ross,Kai Wang,Rami N. Al‐Rohil,Tipu Nazeer,Christine E. Sheehan,Geoff Otto,Jie He,Gary A. Palmer,Roman Yelensky,Doron Lipson,Siraj M. Ali,Sohail Balasubramanian,John A. Curran,(unknown),(unknown),Sean R. Downing,Matthew Hawryluk,Vincent A. Miller,Philip J. Stephens	119
8	Relapsed Classic E-Cadherin ( CDH1 )–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 ( ERBB2 ) Gene Mutations 2013 ·Clinical Cancer Research ·Jeffrey S. Ross,Kai Wang,Christine E. Sheehan,Ann Boguniewicz,Geoff Otto,Sean R. Downing,James Sun,Jie He,John A. Curran,Siraj M. Ali,Roman Yelensky,Doron Lipson,Gary A. Palmer,Vincent A. Miller,Philip J. Stephens	96
9	Use of next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in diverse solid tumor types: The Foundation Medicine (FMI) experience with 2,200+ clinical samples. 2013 ·Journal of Clinical Oncology ·Vincent A. Miller,Jeffrey S. Ross,Kai Wang,Siraj M. Ali,Geoff Otto,John A. Curran,Norma Alonzo Palma,Roman Yelensky,Sean R. Downing,Phil Stephens,Doron Lipson,Gary A. Palmer	5
10	Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer. 2013 ·Journal of Clinical Oncology ·Jeffrey S. Ross,Massimo Cristofanilli,Sean R. Downing,Roman Yelensky,Doron Lipson,Geoff Otto,Gary A. Palmer,Siraj M. Ali,Vincent A. Miller,Phil Stephens	2
11	Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics 2012 ·Breast Cancer Research and Treatment ·Erica L. Mayer,Steven J. Isakoff,Giannoula Klement,Sean R. Downing,Wendy Y. Chen,(unknown),Rebecca Gelman,Eric P. Winer,Harold J. Burstein	38
12	Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity 2012 ·European Urology ·Himisha Beltran,Roman Yelensky,Garrett M. Frampton,Kyung Park,Sean R. Downing,Theresa Y. MacDonald,Mirna Jarosz,Doron Lipson,Scott T. Tagawa,David M. Nanus,Philip J. Stephens,Juan Miguel Mosquera,Maureen Cronin,Mark A. Rubin	330
13	Isolation and Proteomic Analysis of Platelets by SELDI-TOF MS 2011 ·Methods in molecular biology ·Sean R. Downing,Giannoula Klement	12
14	Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: application to mass spec data 2007 ·Bioinformatics ·Yuhyun Park,Sean R. Downing,Dohyun Kim,William C. Hahn,Cheng Li,Philip W. Kantoff,Lee‐Jen Wei	10
15	Simultaneous and Exact Interval Estimates for the Contrast of Two Groups Based on an Extremely High Dimensional Response Variable: Application to Mass Spec Data Analysis 2005 ·Collection of Biostatistics Research Archive ·Yuhyun Park,Sean R. Downing,Cheng Li,William C. Hahn,Philip W. Kantoff,Lee‐Jen Wei	1
16	Elevated levels of prostate‐specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis 2003 ·Molecular Carcinogenesis ·Sean R. Downing,(unknown),Sheri Nixdorf,Kim Ow,Pamela J. Russell,P. Jackson	12
17	Mutations in Ribonuclease L Gene Do NotOccur at a Greater Frequency in Patients with Familial Prostate Cancer Compared with Patients with Sporadic Prostate Cancer 2003 ·PubMed ·Sean R. Downing,(unknown),Miyako Abe,Judith Manola,Daniel J. George,Philip W. Kantoff	15
18	Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression 2001 ·Urologic Oncology Seminars and Original Investigations ·Sean R. Downing,P. Jackson,Pamela J. Russell	28
19	Evidence for post-transcriptional down-regulation of the apoptosis-related genebcl-2 in human colorectal cancer 2000 ·The Journal of Pathology ·Christophe R. Berney,Sean R. Downing,Jia‐Lin Yang,Pamela J. Russell,Philip Crowe	13
20	Elevated expression of FGF-2 does not cause prostate cancer progression in LNCaP cells 1999 ·The Prostate ·Pamela J. Russell,Stephen Bennett,Anthony M. Joshua,Youcheng Yu,Sean R. Downing,Mark A. Hill,Elizabeth A. Kingsley,Rebecca S. Mason,John P. Berry	8

About Sean R. Downing

Sean R. Downing is a scholar working on Cancer Research, Oncology and Biotechnology, having authored 26 papers that have together received 882 indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (6 papers), Prostate Cancer Treatment and Research (5 papers) and Cancer Research and Treatments (3 papers). The work is most often cited by research in Cancer Research (304 citations), Oncology (318 citations) and Pulmonary and Respiratory Medicine (371 citations). Sean R. Downing has collaborated with scholars based in United States, Australia and Ecuador. Frequent co-authors include Doron Lipson, Philip J. Stephens, Roman Yelensky, Mirna Jarosz, Theresa Y. MacDonald, Himisha Beltran, Juan Miguel Mosquera, Garrett M. Frampton, David M. Nanus and Maureen Cronin. Their work appears in journals such as Journal of Clinical Oncology, Bioinformatics and Journal of Fluid Mechanics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact